Skip to main content
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Journal Sections
    • Subscriptions
    • Reviewing
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Collections
      • Clinical Oncology
      • Immuno-oncology
      • Editors' Picks
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • OnlineFirst
    • Editors' Picks
    • Citation
    • Author/Keyword
  • News
    • Cancer Discovery News
    • Journal Press Releases
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Cancer Discovery
Cancer Discovery

Advanced Search

  • Home
  • About
    • The Journal
    • AACR Journals
    • Journal Sections
    • Subscriptions
    • Reviewing
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Collections
      • Clinical Oncology
      • Immuno-oncology
      • Editors' Picks
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • OnlineFirst
    • Editors' Picks
    • Citation
    • Author/Keyword
  • News
    • Cancer Discovery News
    • Journal Press Releases

Table of Contents

In This Issue

  • In This Issue
    In This Issue
    Cancer Discov May 1 2017 7 (5) 443-445; DOI:10.1158/2159-8290.CD-ITI7-5

In the Spotlight

  • In the Spotlight | Free Article
    A Road Map for Precision Cancer Medicine Using Personalized Models
    Gabriele Picco and Mathew J. Garnett
    Cancer Discov May 1 2017 7 (5) 456-458; DOI:10.1158/2159-8290.CD-17-0268

  • In the Spotlight
    Optimizing Next-Generation AML Therapy: Activity of Mutant IDH2 Inhibitor AG-221 in Preclinical Models
    Daniel Thomas and Ravindra Majeti
    Cancer Discov May 1 2017 7 (5) 459-461; DOI:10.1158/2159-8290.CD-17-0270

Research Articles

  • Research Articles | AuthorChoice
    Personalized In Vitro and In Vivo Cancer Models to Guide Precision Medicine
    Chantal Pauli, Benjamin D. Hopkins, Davide Prandi, Reid Shaw, Tarcisio Fedrizzi, Andrea Sboner, Verena Sailer, Michael Augello, Loredana Puca, Rachele Rosati, Terra J. McNary, Yelena Churakova, Cynthia Cheung, Joanna Triscott, David Pisapia, Rema Rao, Juan Miguel Mosquera, Brian Robinson, Bishoy M. Faltas, Brooke E. Emerling, Vijayakrishna K. Gadi, Brady Bernard, Olivier Elemento, Himisha Beltran, Francesca Demichelis, Christopher J. Kemp, Carla Grandori, Lewis C. Cantley and Mark A. Rubin
    Cancer Discov May 1 2017 7 (5) 462-477; DOI:10.1158/2159-8290.CD-16-1154

    A precision medicine approach with high-throughput drug screening in patient-derived tumor organoids and PDX models may identify effective therapeutic strategies in patients without actionable mutations.

  • Research Articles | AuthorChoice
    AG-221, a First-in-Class Therapy Targeting Acute Myeloid Leukemia Harboring Oncogenic IDH2 Mutations
    Katharine Yen, Jeremy Travins, Fang Wang, Muriel D. David, Erin Artin, Kimberly Straley, Anil Padyana, Stefan Gross, Byron DeLaBarre, Erica Tobin, Yue Chen, Raj Nagaraja, Sung Choe, Lei Jin, Zenon Konteatis, Giovanni Cianchetta, Jeffrey O. Saunders, Francesco G. Salituro, Cyril Quivoron, Paule Opolon, Olivia Bawa, Véronique Saada, Angelo Paci, Sophie Broutin, Olivier A. Bernard, Stéphane de Botton, Benoît S. Marteyn, Monika Pilichowska, YingXia Xu, Cheng Fang, Fan Jiang, Wentao Wei, Shengfang Jin, Lee Silverman, Wei Liu, Hua Yang, Lenny Dang, Marion Dorsch, Virginie Penard-Lacronique, Scott A. Biller and Shin-San Michael Su
    Cancer Discov May 1 2017 7 (5) 478-493; DOI:10.1158/2159-8290.CD-16-1034

    Targeted inhibition of IDH2R140Q with the allosteric inhibitor AG-221 reduces production of the oncometabolite 2HG, promotes differentiation of malignant AML blasts, and extends survival in AML xenografts.

  • Research Articles
    Combination Targeted Therapy to Disrupt Aberrant Oncogenic Signaling and Reverse Epigenetic Dysfunction in IDH2- and TET2-Mutant Acute Myeloid Leukemia
    Alan H. Shih, Cem Meydan, Kaitlyn Shank, Francine E. Garrett-Bakelman, Patrick S. Ward, Andrew M. Intlekofer, Abbas Nazir, Eytan M. Stein, Kristina Knapp, Jacob Glass, Jeremy Travins, Kim Straley, Camelia Gliser, Christopher E. Mason, Katharine Yen, Craig B. Thompson, Ari Melnick and Ross L. Levine
    Cancer Discov May 1 2017 7 (5) 494-505; DOI:10.1158/2159-8290.CD-16-1049

    Mutations in TET2 or IDH2 sensitize AML cells to the DNA hypomethylating agents 5-Aza and AG-221, which induce differentiation, reverse aberrant hypermethylation, and cooperate with FLT3 inhibition to suppress AML.

  • Research Articles | AuthorChoice
    BCL6 Antagonizes NOTCH2 to Maintain Survival of Human Follicular Lymphoma Cells
    Ester Valls, Camille Lobry, Huimin Geng, Ling Wang, Mariano Cardenas, Martín Rivas, Leandro Cerchietti, Philmo Oh, Shao Ning Yang, Erin Oswald, Camille W. Graham, Yanwen Jiang, Katerina Hatzi, Xabier Agirre, Eric Perkey, Zhuoning Li, Wayne Tam, Kamala Bhatt, John P. Leonard, Patrick A. Zweidler-McKay, Ivan Maillard, Olivier Elemento, Weimin Ci, Iannis Aifantis and Ari Melnick
    Cancer Discov May 1 2017 7 (5) 506-521; DOI:10.1158/2159-8290.CD-16-1189

    BCL6 binds to and represses NOTCH2 and other NOTCH pathway genes in follicular lymphoma and GC B cells to promote their survival, and BCL6 inhibition suppresses the growth of follicular lymphoma xenografts.

  • Research Articles
    Gut Microbiota Promotes Obesity-Associated Liver Cancer through PGE2-Mediated Suppression of Antitumor Immunity
    Tze Mun Loo, Fumitaka Kamachi, Yoshihiro Watanabe, Shin Yoshimoto, Hiroaki Kanda, Yuriko Arai, Yaeko Nakajima-Takagi, Atsushi Iwama, Tomoaki Koga, Yukihiko Sugimoto, Takayuki Ozawa, Masaru Nakamura, Miho Kumagai, Koichi Watashi, Makoto M. Taketo, Tomohiro Aoki, Shuh Narumiya, Masanobu Oshima, Makoto Arita, Eiji Hara and Naoko Ohtani
    Cancer Discov May 1 2017 7 (5) 522-538; DOI:10.1158/2159-8290.CD-16-0932

    The obesity-associated gut microbial component and metabolite, LTA and DCA, promote COX2-mediated PGE2 production in senescent HSCs to suppress the antitumor immunity in mice fed a high-fat diet and promote HCC.

News in Brief

  • News in Brief
    People
    Cancer Discov May 1 2017 7 (5) 446-446; DOI:10.1158/2159-8290.CD-NB2017-034

  • News in Brief
    Of Cancer and Random Mutations
    Cancer Discov May 1 2017 7 (5) 446-446; DOI:10.1158/2159-8290.CD-NB2017-046

  • News in Brief
    iRECIST Guideline Unveiled for Immunotherapies
    Cancer Discov May 1 2017 7 (5) 446-447; DOI:10.1158/2159-8290.CD-NB2017-037

  • News in Brief
    $100M Africa Initiative Targets Childhood Cancer
    Cancer Discov May 1 2017 7 (5) 447-448; DOI:10.1158/2159-8290.CD-NB2017-038

  • News in Brief
    Gut Microbes May Up PD-1 Inhibitor Response
    Cancer Discov May 1 2017 7 (5) 448-448; DOI:10.1158/2159-8290.CD-NB2017-039

  • News in Brief
    Noted
    Cancer Discov May 1 2017 7 (5) 448-448; DOI:10.1158/2159-8290.CD-NB2017-033

  • News in Brief
    Pembrolizumab Approved for Hodgkin Lymphoma
    Cancer Discov May 1 2017 7 (5) OF1-OF1; DOI:10.1158/2159-8290.CD-NB2017-044

  • News in Brief
    Profiling Response, Resistance to Immunotherapy
    Cancer Discov May 1 2017 7 (5) OF2-OF2; DOI:10.1158/2159-8290.CD-NB2017-045

  • News in Brief
    Ribociclib Approved for Advanced Breast Cancer
    Cancer Discov May 1 2017 7 (5) OF3-OF3; DOI:10.1158/2159-8290.CD-NB2017-043

  • News in Brief
    Monitoring Resistance, Recurrence in NSCLC
    Cancer Discov May 1 2017 7 (5) OF4-OF4; DOI:10.1158/2159-8290.CD-NB2017-042

  • News in Brief
    Budget Cuts Would Harm Research and Patients
    Cancer Discov May 1 2017 7 (5) OF5-OF5; DOI:10.1158/2159-8290.CD-NB2017-041

  • News in Brief
    CRISPR Meets CAR T-cell Therapy
    Cancer Discov May 1 2017 7 (5) OF6-OF6; DOI:10.1158/2159-8290.CD-NB2017-040

  • News in Brief
    A Different Path for Harnessing TRAIL
    Cancer Discov May 1 2017 7 (5) OF7-OF7; DOI:10.1158/2159-8290.CD-NB2017-036

  • News in Brief
    Immunotherapy Beats Chemo for Bladder Cancer
    Cancer Discov May 1 2017 7 (5) OF8-OF8; DOI:10.1158/2159-8290.CD-NB2017-035

News in Depth

  • News in Depth
    Converging on RAS
    Cancer Discov May 1 2017 7 (5) 449-449; DOI:10.1158/2159-8290.CD-ND2017-001

Research Watch

  • Brain Tumors

    • Research Watch
      ALKBH5 Drives FOXM1 Expression to Promote Brain Tumor Stem Cell Growth
      Cancer Discov May 1 2017 7 (5) OF9-OF9; DOI:10.1158/2159-8290.CD-RW2017-060

    • Research Watch
      An Anti-CD47 Antibody Is Effective in Pediatric Brain Tumor Models
      Cancer Discov May 1 2017 7 (5) 453-453; DOI:10.1158/2159-8290.CD-RW2017-057

  • Breast Cancer

    • Research Watch
      PI3K Signaling Regulates ER Activity via KMT2D in ER+ Breast Cancer
      Cancer Discov May 1 2017 7 (5) 455-455; DOI:10.1158/2159-8290.CD-RW2017-063

  • Clinical Trials

    • Research Watch
      MK-8242 Is Active in Patients with p53 Wild-Type Advanced Solid Tumors
      Cancer Discov May 1 2017 7 (5) 451-451; DOI:10.1158/2159-8290.CD-RW2017-047

    • Research Watch
      HER2+ Tumor Molecular Subtypes Predict Response to Dual HER2 Blockade
      Cancer Discov May 1 2017 7 (5) OF10-OF10; DOI:10.1158/2159-8290.CD-RW2017-048

    • Research Watch
      Rechallenge with BRAF and MEK Inhibitors Has Antitumor Activity
      Cancer Discov May 1 2017 7 (5) 452-452; DOI:10.1158/2159-8290.CD-RW2017-052

  • DNA Damage

    • Research Watch
      Ultraviolet-Induced DNA Damage Promotes RNA m6A Methylation
      Cancer Discov May 1 2017 7 (5) 455-455; DOI:10.1158/2159-8290.CD-RW2017-058

  • Epigenetics

    • Research Watch
      Inhibition of EZH2 or BET Suppresses Diffuse Intrinsic Pontine Glioma
      Cancer Discov May 1 2017 7 (5) OF11-OF11; DOI:10.1158/2159-8290.CD-RW2017-050

  • Immunology

    • Research Watch
      Targeting Class IIa HDACs May Suppress Breast Tumors and Metastases
      Cancer Discov May 1 2017 7 (5) 451-451; DOI:10.1158/2159-8290.CD-RW2017-053

  • Immunotherapy

    • Research Watch
      Combination Immunotherapy Targets Castration-Resistant Prostate Cancer
      Cancer Discov May 1 2017 7 (5) OF12-OF12; DOI:10.1158/2159-8290.CD-RW2017-064

    • Research Watch
      PD-1 Blockade–Mediated Rescue of Exhausted T Cells Requires CD28
      Cancer Discov May 1 2017 7 (5) 453-453; DOI:10.1158/2159-8290.CD-RW2017-055

  • Kinase Inhibitors

    • Research Watch
      Allosteric Plus Catalytic BCR–ABL1 Inhibitors Promote Durable Responses
      Cancer Discov May 1 2017 7 (5) 454-454; DOI:10.1158/2159-8290.CD-RW2017-062

  • Leukemia

    • Research Watch
      ETO2–GLIS2 Drives the Transcriptional Program Underlying AMKL
      Cancer Discov May 1 2017 7 (5) OF13-OF13; DOI:10.1158/2159-8290.CD-RW2017-059

    • Research Watch
      ENL Is an Essential Acetyl-Histone Reader in Acute Myeloid Leukemia
      Cancer Discov May 1 2017 7 (5) OF14-OF14; DOI:10.1158/2159-8290.CD-RW2017-049

  • Metastasis

    • Research Watch
      Complement Component 3 Promotes Leptomeningeal Metastasis
      Cancer Discov May 1 2017 7 (5) OF15-OF15; DOI:10.1158/2159-8290.CD-RW2017-051

  • Multiple Myeloma

    • Research Watch
      T-cell Bispecific Antibodies Suppress Multiple Myeloma
      Cancer Discov May 1 2017 7 (5) 452-452; DOI:10.1158/2159-8290.CD-RW2017-054

  • Prostate Cancer

    • Research Watch
      Peptidomimetic Inhibitors Target ERG Gene Fusions in Prostate Cancer
      Cancer Discov May 1 2017 7 (5) 454-454; DOI:10.1158/2159-8290.CD-RW2017-061

  • Splicing

    • Research Watch
      Aryl Sulfonamides Target Pre-mRNA Splicing in Cancer
      Cancer Discov May 1 2017 7 (5) OF16-OF16; DOI:10.1158/2159-8290.CD-RW2017-056

  • Structural Biology

    • Research Watch
      The Bipartite Substrate Binding Site in MRP1 Recognizes Diverse Structures
      Cancer Discov May 1 2017 7 (5) OF17-OF17; DOI:10.1158/2159-8290.CD-RW2017-046

Back to top
PreviousNext
Cancer Discovery: 7 (5)
May 2017
Volume 7, Issue 5
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Editorial Board (PDF)

Sign up for alerts

Jump to

  • In This Issue
  • In the Spotlight
  • Research Articles
  • News in Brief
  • News in Depth
  • Research Watch
    • Brain Tumors
    • Breast Cancer
    • Clinical Trials
    • DNA Damage
    • Epigenetics
    • Immunology
    • Immunotherapy
    • Kinase Inhibitors
    • Leukemia
    • Metastasis
    • Multiple Myeloma
    • Prostate Cancer
    • Splicing
    • Structural Biology
Advertisement
  • Most Cited
  • Most Read
Loading
  • The cBio Cancer Genomics Portal: An Open Platform for Exploring Multidimensional Cancer Genomics Data
  • Macrophages Regulate Response to Chemotherapy
  • Core Resistance Mechanisms and Genetic Evolution of Melanoma under BRAF Inhibitor Selection
  • EGFR Mediates RAF Inhibitor Resistance in BRAF-Mutant Colorectal Cancer
  • Novel Mutant-Selective EGFR Inhibitor Overcomes Drug Resistance
More...
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook   Twitter   LinkedIn   YouTube   RSS

Articles

  • OnlineFirst
  • Current Issue
  • Past Issues

Info For

  • Authors
  • Subscribers
  • Advertisers
  • Librarians
  • Reviewers

About Cancer Discovery

  • About the Journal
  • Editors
  • Journal Sections
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2019 by the American Association for Cancer Research.

Cancer Discovery
eISSN: 2159-8290
ISSN: 2159-8274

Advertisement